ibx
IBX: Biotech Bubble - MagSense® Makes No Sense at These Levels
Updated 8 Oct 2025
Clinical-stage biotechnology company trading at $1.62 vs fair value $0.13, facing 65% Phase 2 failure probability with extreme dilution risk ahead.
View note